- Home
- ALX vs ORIC Comparison
ALX vs ORIC Comparison
Compare ALX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- ORIC
- Stock Information
- Founded
- ALX 1928
- ORIC 2014
- Country
- ALX United States
- ORIC United States
- Employees
- ALX N/A
- ORIC N/A
- Industry
- ALX Real Estate Investment Trusts
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- ORIC Health Care
- Exchange
- ALX Nasdaq
- ORIC Nasdaq
- Market Cap
- ALX 1.2B
- ORIC 1.1B
- IPO Year
- ALX N/A
- ORIC 2020
- Fundamental
- Price
- ALX $232.14
- ORIC $13.99
- Analyst Decision
- ALX
- ORIC Strong Buy
- Analyst Count
- ALX 0
- ORIC 8
- Target Price
- ALX N/A
- ORIC $16.57
- AVG Volume (30 Days)
- ALX 85.3K
- ORIC 1.7M
- Earning Date
- ALX 11-03-2025
- ORIC 11-11-2025
- Dividend Yield
- ALX 7.75%
- ORIC N/A
- EPS Growth
- ALX N/A
- ORIC N/A
- EPS
- ALX 7.28
- ORIC N/A
- Revenue
- ALX $218,089,000.00
- ORIC N/A
- Revenue This Year
- ALX N/A
- ORIC N/A
- Revenue Next Year
- ALX N/A
- ORIC N/A
- P/E Ratio
- ALX $31.44
- ORIC N/A
- Revenue Growth
- ALX N/A
- ORIC N/A
- 52 Week Low
- ALX $184.76
- ORIC $3.90
- 52 Week High
- ALX $260.84
- ORIC $14.93
- Technical
- Relative Strength Index (RSI)
- ALX 46.29
- ORIC 67.45
- Support Level
- ALX $230.08
- ORIC $13.24
- Resistance Level
- ALX $243.60
- ORIC $14.93
- Average True Range (ATR)
- ALX 6.54
- ORIC 0.81
- MACD
- ALX -0.64
- ORIC 0.25
- Stochastic Oscillator
- ALX 13.10
- ORIC 80.50
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.